Ankylosing Spondylitis News and Research

RSS
Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.
Reduced rheumatoid arthritis risk in schizophrenia linked to underreporting

Reduced rheumatoid arthritis risk in schizophrenia linked to underreporting

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen launches Inflectra into Central and Eastern Europe

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Women taking immunosuppressive medications during pregnancy do not put their babies at risk

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

Anti-tumor necrosis factor drugs modestly reduce risk of acute coronary syndrome

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

AbbVie announces HUMIRA phase II study results for treating hidradenitis suppurativa

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Compatibility gene may influence finding life partner as well as our health, individuality

Compatibility gene may influence finding life partner as well as our health, individuality

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Novel antibody biomarkers could significantly improve diagnosis in RA, study shows

Using Swiss ball improves walking performance and muscle strength in AS patients

Using Swiss ball improves walking performance and muscle strength in AS patients

University of Oxford researchers receive grant to study genes that contribute to ankylosing spondylitis

University of Oxford researchers receive grant to study genes that contribute to ankylosing spondylitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Simponi injection gets FDA approval to treat adults with ulcerative colitis

POZEN announces revenue of $1.4 million for first quarter 2013

POZEN announces revenue of $1.4 million for first quarter 2013

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Study: Use of anti-TNF therapies in RA patients does not increase risk of herpes zoster

Researchers unravel dual role of tumor necrosis factor in TB

Researchers unravel dual role of tumor necrosis factor in TB

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study

RA patients who initiate anti-TNF therapies do not have higher risk of shingles: Study